Alamar Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yuling Luo
- Full Time Employees
- 222
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 47071 Bayside Parkway Fremont CA United States of America 94538
- IPO Date
- Apr 17, 2026
- CIK
- 0002104204
- Website
- alamarbio.com
- Similar Companies
- Business
- Alamar Biosciences, Inc. engages in precision proteomics for ultra-sensitive, high-plex protein analysis across discovery, translational research, and diagnostics. The company develops automated platforms, proprietary chemistry, and multiplexed assays that enable measurement of low-abundance biomarkers with high dynamic range, supporting biomarker discovery, assay development, and clinical diagnostics. Main products and services - ARGO High Throughput System: fully automated, high-throughput proteomics instrument enabling ultra-sensitive protein analysis with short hands-on time; supports rapid from-sample-to-data workflows; designed for large-scale biomarker measurements across multiplex levels. - NULISA Chemistry: proprietary sequential capture and release chemistry that reduces background signals and enhances sensitivity and dynamic range; enables both nucleic acid readouts via qPCR and sequencing readouts via NGS. - NULISAseq Panels: multiplexed biomarker panels built on NULISA chemistry, including inflammation and immune-related panels with 200+ markers (examples include inflammation-focused panels) designed for rapid, high-sensitivity readouts. - Attobody and related antibody platforms: antibody-based tools and reagents used to support high-plex proteomic profiling and assay development. - Analytical software: integrated software for data acquisition, processing, and interpretation to deliver actionable proteomics results. Latest major company changes - Strategic partnership expansions to broaden biomarker assay development capabilities, including collaborations with ADx NeuroSciences for customized blood-based biomarker solutions to accelerate neurodegenerative disease research and clinical development. - Funding rounds to accelerate product development and commercialization of NULISAseq panels, including investment aimed at expanding inflammation and immune-marker panels, and scaling ARGO System deployment. - Ongoing expansion of global footprint and customer base, with rapid uptake of ARGO HT System across multiple countries, indicating strong market adoption and geographic reach. Additional context - Industry and business segments: precision proteomics; biomarker discovery; translational research; diagnostics assay development; contract research support. - Target markets: researchers in academia; biopharma and biotech companies; clinical laboratories; diagnostic developers requiring ultra-high sensitivity, multiplex protein analyses. - Geographic operations: global presence with customers in numerous countries; ARGO System adoption across multiple regions; headquarters and primary operations in the United States with international collaboration and distribution. - Founding year and headquarters: established in the mid-2010s; headquarters in the United States (broader corporate operations and manufacturing aligned with R&D facilities). - Sub/parent relationships: operates as an independent biotechnology company specializing in NULISA chemistry and ARGO platform; collaborates with pharmaceutical/biotech partners and contract research organizations to broaden assay capabilities and market reach.
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃，旨在推動神經退行性疾病相關的血漿生物標記研究
Alamar Biosciences 联合多所顶尖研究型大学推出全国性研究计划，推进神经退行性疾病血液生物标志物相关研究
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
Alamar Biosciences Reports First Quarter 2026 Financial Results
Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026
Alamar Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ
Alamar Biosciences: Looking For An Early Detection
Alamar Biosciences valued at $1.5 billion as shares jump in Nasdaq debut
Alamar Biosciences Burns Cash In Runup To IPO